fig2
Figure 2. SVR24 rate with GT1 or GT2. All patients achieved SVR24 regardless of GT1 or GT2. SVR: sustained virological response; DCV: daclatasvir; ASV: asunaprevir; SOF: sofosbuvir; LDV: ledipasvir; RBV: ribavirin
Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)
Navigation
Follow Us
Navigation
Portico
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/
Follow OAE
